Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis

Objectives: Methotrexate is successfully used in the treatment of arthritis but little is known about its effects on extra-articular manifestations of rheumatoid arthritis. We focused this work on the incidence and clinical course of extra-articular manifestations during long-term treatment with met...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
1993
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/27919
Acceso en línea:
https://repository.urosario.edu.co/handle/10336/27919
Palabra clave:
Methotrexate
Vasculitis
Rights
License
Bloqueado (Texto referencial)
id EDOCUR2_d131ac3f2ae4c0de2f076d14545ac9fb
oai_identifier_str oai:repository.urosario.edu.co:10336/27919
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 19474778600e8938956-af14-46bd-9749-62565a90def1363a398e-e9c8-42e8-bf3b-ad30173847266fdc324f-d229-4e2c-8776-e4dbea7e7b64799436366002020-08-19T14:44:38Z2020-08-19T14:44:38Z1993Objectives: Methotrexate is successfully used in the treatment of arthritis but little is known about its effects on extra-articular manifestations of rheumatoid arthritis. We focused this work on the incidence and clinical course of extra-articular manifestations during long-term treatment with methotrexate.Methods: The effect of methotrexate on extra-articular manifestations was investigated in 176 patients with rheumatoid arthritis who had obtained, in a prospective study, a good clinical response to methotrexate (10 mg/week) taken for 33 months (range 4-68).Results: Before taking methotrexate, 44 patients (25.1%) had extra-articular manifestations: nodules (n = 40) and vasculitis (n = 9). With methotrexate, nodulosis and vasculitis were stable in 31 cases, improved in 3 and worsened in 10 (23%). Among the 132 patients without extra-articular manifestations before methotrexate therapy, 15 (11%) developed accelerated nodulosis preferentially located on the fingers, 7 had a vasculitis and 3 a pericarditis during methotrexate therapy. Extra-articular manifestations occurred between 1 and 24 months of initiating methotrexate therapy. Rheumatoid factor was positive in 88% of the patients with extra-articular manifestations. No relationship was noted between extra-articular manifestations and HLA type or antinuclear antibodies. In 3 out of 4 patients who developed accelerated nodulosis while taking methotrexate, the addition of hydroxychloroquine (400 mg/day) resulted in a significant reduction in the number and size of the nodules within 3 to 10 months after starting combined therapy.Conclusion: These data suggest that methotrexate is not effective in the treatment of extra-articular manifestations in rheumatoid arthritis and that nodulosis may occur in about 11% of patients taking methotrexate therapy for rheumatoid arthritis. The combination of hydroxychloroquine and methotrexate may have a beneficial effect on nodulosis that needs to be evaluated.application/pdfISSN: 1165-0478https://repository.urosario.edu.co/handle/10336/27919engNational Center for Biotechnology Information160No. 3153The European journal of medicineVol. 2The European journal of medicine, ISSN: 1165-0478, Vol.2, No.3 (1993); pp. 153-160https://pubmed.ncbi.nlm.nih.gov/8261056/Bloqueado (Texto referencial)http://purl.org/coar/access_right/c_14cbThe European journal of medicineinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURMethotrexateVasculitisAccelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritisNódulosis acelerada y manifestaciones sistémicas durante el tratamiento con metotrexato para la artritis reumatoidearticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Anaya, Juan-ManuelSany, J.Combe, BDidry, CGutiérrez Peláez, Miguel10336/27919oai:repository.urosario.edu.co:10336/279192021-08-10 16:53:37.896https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
dc.title.TranslatedTitle.spa.fl_str_mv Nódulosis acelerada y manifestaciones sistémicas durante el tratamiento con metotrexato para la artritis reumatoide
title Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
spellingShingle Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
Methotrexate
Vasculitis
title_short Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
title_full Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
title_fullStr Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
title_full_unstemmed Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
title_sort Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
dc.subject.keyword.spa.fl_str_mv Methotrexate
Vasculitis
topic Methotrexate
Vasculitis
description Objectives: Methotrexate is successfully used in the treatment of arthritis but little is known about its effects on extra-articular manifestations of rheumatoid arthritis. We focused this work on the incidence and clinical course of extra-articular manifestations during long-term treatment with methotrexate.Methods: The effect of methotrexate on extra-articular manifestations was investigated in 176 patients with rheumatoid arthritis who had obtained, in a prospective study, a good clinical response to methotrexate (10 mg/week) taken for 33 months (range 4-68).Results: Before taking methotrexate, 44 patients (25.1%) had extra-articular manifestations: nodules (n = 40) and vasculitis (n = 9). With methotrexate, nodulosis and vasculitis were stable in 31 cases, improved in 3 and worsened in 10 (23%). Among the 132 patients without extra-articular manifestations before methotrexate therapy, 15 (11%) developed accelerated nodulosis preferentially located on the fingers, 7 had a vasculitis and 3 a pericarditis during methotrexate therapy. Extra-articular manifestations occurred between 1 and 24 months of initiating methotrexate therapy. Rheumatoid factor was positive in 88% of the patients with extra-articular manifestations. No relationship was noted between extra-articular manifestations and HLA type or antinuclear antibodies. In 3 out of 4 patients who developed accelerated nodulosis while taking methotrexate, the addition of hydroxychloroquine (400 mg/day) resulted in a significant reduction in the number and size of the nodules within 3 to 10 months after starting combined therapy.Conclusion: These data suggest that methotrexate is not effective in the treatment of extra-articular manifestations in rheumatoid arthritis and that nodulosis may occur in about 11% of patients taking methotrexate therapy for rheumatoid arthritis. The combination of hydroxychloroquine and methotrexate may have a beneficial effect on nodulosis that needs to be evaluated.
publishDate 1993
dc.date.created.spa.fl_str_mv 1993
dc.date.accessioned.none.fl_str_mv 2020-08-19T14:44:38Z
dc.date.available.none.fl_str_mv 2020-08-19T14:44:38Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.issn.none.fl_str_mv ISSN: 1165-0478
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/27919
identifier_str_mv ISSN: 1165-0478
url https://repository.urosario.edu.co/handle/10336/27919
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 160
dc.relation.citationIssue.none.fl_str_mv No. 3
dc.relation.citationStartPage.none.fl_str_mv 153
dc.relation.citationTitle.none.fl_str_mv The European journal of medicine
dc.relation.citationVolume.none.fl_str_mv Vol. 2
dc.relation.ispartof.spa.fl_str_mv The European journal of medicine, ISSN: 1165-0478, Vol.2, No.3 (1993); pp. 153-160
dc.relation.uri.spa.fl_str_mv https://pubmed.ncbi.nlm.nih.gov/8261056/
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_14cb
dc.rights.acceso.spa.fl_str_mv Bloqueado (Texto referencial)
rights_invalid_str_mv Bloqueado (Texto referencial)
http://purl.org/coar/access_right/c_14cb
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv National Center for Biotechnology Information
dc.source.spa.fl_str_mv The European journal of medicine
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167633581309952